Jehee Suh, CEO of Inocras

Your Story

Q1. What was the defining moment or insight that led you to take the helm of Inocras?

What drew me to Inocras was the realization that whole-genome sequencing had already proven its scientific value, but had not yet been translated into routine clinical practice in a way that was practical for physicians or meaningful for patients. Too often, the conversation stopped at technical possibility. What I saw in Inocras was the opportunity to close that gap — to turn whole-genome data into something clinicians could actually use in everyday decision-making.

‍

The other defining insight was that this would not be solved by sequencing alone. The real unlock is bioinformatics: the ability to interpret the full genome accurately, consistently, and in a way that fits the realities of care. That combination of scientific depth and clinical pragmatism is what convinced me this was a company worth leading.

‍

Q2. In simple terms, what does Inocras do — and why does it matter for patients?

Inocras helps doctors get a much more complete view of a patient's genome so they can make better decisions about diagnosis, treatment, and monitoring. In oncology, for example, that means moving beyond narrower tests that look only at selected genomic regions and instead using whole-genome analysis to understand the full molecular picture of a tumor.

‍

Why that matters is simple: better information leads to better choices. If we succeed, patients gain access to more precise treatment strategies, more informed monitoring over time, and potentially options that would be missed with more limited testing. Our goal is to make the full genome clinically useful, not just scientifically interesting.

‍

Q3. Why do you believe whole-genome sequencing is reaching an inflection point now?

For many years, whole-genome sequencing was viewed as powerful but impractical for routine care. That is changing because the core barriers — cost, workflow complexity, and interpretive limitations — are being addressed simultaneously. What the field needs now is not more promise, but more implementation.

‍

We believe the inflection point arrives when clinical validation, evidence of utility, and market readiness begin to align. That is when a technology moves from being impressive to being standard. Our job is to help accelerate that transition responsibly and at scale.

‍

The Science & The Strategy

Q4. What sets Inocras apart from others working in this space?

What differentiates Inocras is that we are bioinformatics-led at our core. We are not simply generating genomic data — we are focused on translating whole-genome data into curated, clinically actionable insight. That matters because whole-genome sequencing only becomes valuable in care when the analysis is accurate, scalable, and usable by clinicians.

‍

Our platform is built around proprietary analytics refined through extensive work on real patient cases. We are committed to delivering that depth in a way that supports practical clinical workflows, whether in tumor profiling, rare disease diagnosis, or ultra-sensitive residual disease detection. In our view, the real differentiator is not just seeing more of the genome, but making more of it matter.

‍

Q5. How is AI changing the future of whole-genome-based cancer care?

AI becomes most powerful when it is trained on comprehensive, high-quality data. In cancer, that means whole-genome data — because cancer is fundamentally a disease of the genome. Our view is that AI will increasingly help uncover patterns, biomarkers, and clinical signals that narrower datasets simply cannot capture.

‍

For Inocras, that is a central part of the future. We are focused not only on interpreting genomes today, but on building the foundation for what we call cancer genome intelligence: a system in which large, curated whole-genome datasets can support smarter diagnosis, monitoring, and treatment decisions over time.

‍

Q6. What is the biggest challenge you are facing right now, and how are you tackling it?

The biggest challenge is not proving that whole-genome sequencing is powerful — that is already well understood. The challenge is making it standard: generating enough clinical evidence, operational consistency, and economic rationale for whole-genome analysis to become part of routine care rather than an exception.

‍

We are tackling this in a disciplined way. First, we continue to strengthen the data and clinical evidence behind our platform. Second, we focus on standardization so that our solutions fit real clinical workflows. Third, we work with leading institutions and partners who can help demonstrate utility at scale. In genomics, adoption happens when science, workflow, and economics move together.

‍

Q7. What has been your most important milestone to date, and what is next?

One of our most important milestones has been demonstrating that whole-genome-based testing can work in real clinical settings — not only in research environments. That includes building a validated operational platform, supporting adoption by oncologists in everyday practice, and expanding the evidence base for its clinical utility.

‍

More recently, we have seen important external validation through collaborations and published studies, including whole-genome work in breast cancer and upcoming presentations with Broad Institute researchers at AACR 2026. The next milestone is translating that scientific and clinical momentum into broader U.S. market adoption, where evidence generation, strategic partnerships, and reimbursement progress will be critical.

‍

Leadership & Ecosystem

Q8. What has surprised you most about being a CEO in life sciences?

What surprised me most is how much of the role is about timing and translation. In life sciences, it is not enough to have strong science. You have to know when a market is ready, when evidence is sufficient, when partners are aligned, and how to translate a complex technical story into something clinicians, investors, and collaborators can each understand on their own terms.

‍

I also underestimated how much organizational clarity matters. In a science-driven company, people are naturally drawn to what is technically possible. The CEO's role is to keep connecting that possibility to what will create the most impact for patients — and the most momentum for the business.

‍

Q9. What role does San Diego's life sciences ecosystem play in Inocras's growth?

San Diego has been an important home base for Inocras because it sits at the intersection of biotechnology, genomics, clinical research, and entrepreneurial talent. For a company like ours, that matters not just for hiring, but for building the right network of collaborators across hospitals, research institutions, technology partners, and the broader precision medicine community.

‍

Ecosystem matters especially when you are trying to help shift an entire field toward broader adoption of whole-genome-based care. Our move to San Diego positioned us closer to the center of the global genomics ecosystem, accelerating the kinds of conversations, partnerships, and visibility that are difficult to replicate elsewhere.

‍

Looking Ahead

Q10. What is one thing about the life sciences industry you would change — and what gives you optimism?

If I could change one thing, it would be the industry's tendency to adopt innovation more slowly than patients can afford. In many areas, the science moves faster than the systems around it — whether that means reimbursement frameworks, clinical adoption pathways, infrastructure, or regulatory readiness. That gap can delay the real-world impact of technologies that are already capable of improving care.

‍

What gives me optimism is that the direction is unmistakable. The industry is becoming more data-driven, more computational, and more open to approaches that were once considered too complex for routine use. In genomics especially, I believe we are approaching an inflection point where whole-genome analysis will no longer be seen as aspirational — but essential.

‍

‍

About The Big4Bio CEO Weekly Q&A

Every Monday, Big4Bio spotlights a life sciences CEO from one of our eight coverage regions — Boston, San Francisco Bay Area, San Diego, Philadelphia, New York City, the Capital Region, Los Angeles, and Seattle. Each feature is promoted across all eight Big4Bio daily newsletters, reaching 30,000+ life sciences professionals. CEO participation is complimentary and editorial — every CEO approves the final Q&A before publication.

‍

Are you a life sciences CEO or do you represent one? Contact Big4Bio editor Marie Daghlian at marie@big4bio.com to be considered for an upcoming feature.